| Identification | Back Directory | [Name]
4-Piperidinecarboxylic acid, 1-[(3R)-3-[[4-[[[4-[4-[3-[2-(4-chlorophenyl)-5-methyl-1-(1-methylethyl)-4-(methylsulfonyl)-1H-pyrrol-3-yl]-5-fluorophenyl]-1-piperazinyl]phenyl]amino]sulfonyl]-2-[(trifluoromethyl)sulfonyl]phenyl]amino]-4-(phenylthio)butyl]- | [CAS]
1619923-32-8 | [Synonyms]
BM-1244 | [Molecular Formula]
C54H59ClF4N6O8S4 | [MDL Number]
MFCD34574527 | [MOL File]
1619923-32-8.mol | [Molecular Weight]
1159.79 |
| Hazard Information | Back Directory | [Biological Activity]
BM-1244 is a potent Bcl-xL/Bcl-2 inhibitor with Kis of 134 and 450 nM for Bcl- xL and Bcl-2, respectively. BM-1244 inhibits senescent fibroblasts (SnCs) with an EC50 of 5 nM. (From patent WO2019033119A1)[1]. | [storage]
Store at -20°C | [References]
[1]. Jill Hopkins, et al. Treatment of ophthalmic conditions such as macular degeneration, glaucoma, and diabetic retinopathy using pharmaceutical agents that eliminate senescent cells. WO2019033119A1. [2]. Kim R. Unknotting the roles of Bcl-2 and Bcl-xL in cell death. Biochem Biophys Res Commun. 2005;333(2):336-343. |
|
|